Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis

Gastroenterology

Volumn 146, Issue 1, 2014, Pages

  Feagan, Brian G ^a   Sandborn, William J ^b   Lazar, Andreas ^c   Thakkar, Roopal B ^c   Huang, Bidan ^c   Reilly, Nattanan ^c   Chen, Naijun ^c   Yang, Mei ^c   Skup, Martha ^c   Mulani, Parvez ^c   Chao, Jingdong ^c  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ABBVIE INC   (United States)

Author keywords

Anti TNF; Colectomy; Inflammatory Bowel Disease; Randomized Placebo Controlled Study

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; MERCAPTOPURINE; PLACEBO;

ADULT; ARTICLE; COLON RESECTION; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HOSPITALIZATION; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 84890688226     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.09.032     Document Type: Article

References (14)

1. I. Ordás, L. Eckmann, and M. Talamini Ulcerative colitis Lancet 380 2012 1606 1619
2. C. Mowat, A. Cole, and A. Windsor Guidelines for the management of inflammatory bowel disease in adults Gut 60 2011 571 607
3. A. Kornbluth, D.V. Sachar Practice Parameters Committee of the American College of Gastroenterology Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee Am J Gastoenterol 105 2010 501 523
4. R.D. Cohen, A.P. Yu, and E.Q. Wu Systematic review: the costs of ulcerative colitis in Western countries Aliment Pharmacol Ther 31 2010 693 707
5. W. Reinisch, W.J. Sandborn, and M. Bala Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis Inflamm Bowel Dis 13 2007 1135 1140
6. M. Bewtra, C. Su, and J.D. Lewis Trends in hospitalization rates for inflammatory bowel disease in the United States Clin Gastroenterol Hepatol 5 2007 597 601
7. A. Sonnenberg Hospitalization for inflammatory bowel disease in the United States between 1970 and 2004 J Clin Gastroenterol 43 2009 297 300
8. Cohen RD, Rizzo J, Yang M, et al. Direct and indirect utilization and costs associated with ulcerative colitis. Poster presentation P984 at the American College of Gastroenterology Annual Scientific Meeting, October 19-24, 2012; Las Vegas, NV.
9. W. Reinisch, W.J. Sandborn, and D.W. Hommes Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial Gut 60 2011 780 787
10. W. Reinisch, W.J. Sandborn, and R. Panaccione 52-week efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants Inflamm Bowel Dis 19 2013 1700 1709
11. W.J. Sandborn, G.V. Van Assche, and W. Reinisch Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis Gastroenterology 142 2012 257 265
12. B.G. Feagan, R. Panaccione, and W.J. Sandborn Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study Gastroenterology 135 2008 1493 1499
13. W.J. Sandborn, P. Rutgeerts, and B.G. Feagan Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab Gastroenterology 137 2009 1250 1260
14. O. Miettinen Estimability and estimation in case-referent studies Am J Epidemiol 103 1976 226 235